NICE publishes final guidance on PharmaMar's Yondelis and UCB's Cimzia
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final positive guidance on PharmaMar's Yondelis (trabectedin) for the treatment of advanced soft tissue sarcoma, and UCB's Cimzia (certolizumab pegol) for rheumatoid arthritis (RA). The institute was initially set to decline both drugs.
You may also be interested in...
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.